Conscripts of the infinite armada: systemic cancer therapy using nanomaterials.
Conscripts of the infinite armada: systemic cancer therapy using nanomaterials.
复制标题
DOI：
10.1038/nrclinonc.2010.38
复制
发表时间：
2010-05
影响因子：
78.8
通讯作者：
McDevitt, Michael R.
中科院分区：
文献类型：
--
作者：
Scheinberg, David A.;Villa, Carlos H.;Escorcia, Freddy E.;McDevitt, Michael R.
临床纳米材料领域在稳步扩大，在过去十年中，美国政府机构为相关研究拨款超过十亿美元。第一代使用新型纳米材料的抗癌药物已成功广泛应用。较新的纳米材料作为潜在的多功能治疗药物越来越受到关注；这些药物因其大小和形状而具有新的特性。这些药物的新特性可能会提高对癌症的选择性、改变药代动力学、增强细胞毒性作用以及具备同时成像的能力。在与能与细胞表面抗原或受体相互作用的癌症靶向反应性配体结合后，这些新的构建体能够传递细胞溶解和成像有效载荷。这些分子也给药物开发带来了新的挑战。虽然纳米级分子与蛋白质大小相似，但人体细胞、组织和器官对非生物材料的反应模式尚未被充分了解，因为大多数细胞和代谢过程是为了处理球状的、可被酶降解的分子而进化的。我们讨论不同材料的实例，以阐明这些纳米材料药物开发和未来应用的有趣原理，重点强调实现治疗目标可能面临的药理学和安全性障碍。
The field of clinical nanomaterials is enlarging steadily, with more than a billion US dollars of funding allocated to research by US government agencies in the past decade. The first generation of anti-cancer agents using novel nanomaterials has successfully entered widespread use. Newer nanomaterials are garnering increasing interest as potential multifunctional therapeutic agents; these drugs are conferred novel properties, by virtue of their size and shape. The new features of these agents could potentially allow increased cancer selectivity, changes in pharmacokinetics, amplification of cytotoxic effects, and simultaneous imaging capabilities. After attachment to cancer target reactive-ligands, which interact with cell-surface antigens or receptors, these new constructs can deliver cytolytic and imaging payloads. The molecules also introduce new challenges for drug development. While nanoscale molecules are of a similar size to proteins, the paradigms for how cells, tissues and organs of the body react to the non-biological materials are not well understood, because most cellular and metabolic processes have evolved to deal with globular, enzyme degradable molecules. We discuss examples of different materials to illustrate interesting principles for development and future applications of these nanomaterial medicines with emphasis on the possible pharmacologic and safety hurdles for accomplishing therapeutic goals.
登录
查看更多内容
影响因子：
4.9
作者：
Alexis F;Pridgen E;Molnar LK;Farokhzad OC
通讯作者：
Farokhzad OC
影响因子：
17.1
作者：
Bhirde, Ashwin A.;Patel, Vyomesh;Gavard, Julie;Zhang, Guofeng;Sousa, Alioscka A.;Masedunskas, Andrius;Leapman, Richard D.;Weigert, Roberto;Gutkind, J. Silvio;Rusling, James F.
通讯作者：
Rusling, James F.
影响因子：
10.8
作者：
Burns AA;Vider J;Ow H;Herz E;Penate-Medina O;Baumgart M;Larson SM;Wiesner U;Bradbury M
通讯作者：
Bradbury M
DOI：
10.1038/nrmicro1927
发表时间：
2008-07
期刊：
Nature reviews. Microbiology
影响因子：
--
作者：
通讯作者：
--
影响因子：
5.5
作者：
Boxall, Alistair B. A.;Tiede, Karen;Chaudhry, Qasim
通讯作者：
Chaudhry, Qasim